Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» AbbVie
AbbVie
AbbVie chief's $20M-plus pay—and company jet-setting—headed skyward in 2016
Fierce Pharma
Fri, 03/10/17 - 09:53 am
AbbVie
Pharma CEOs
executive pay
Richard Gonzalez
2016 went out like a lamb in the biopharma M&A world. Will it roar back in 2017? Plus, top 10 deals
Endpoints
Wed, 02/22/17 - 11:43 am
M&A
Shire
Baxalta
Pfizer
Medivation
Mylan
Meda
AbbVie
Stemcentrx
Anacor
AbbVie Announces $5 Billion Increase to Stock Repurchase Program
Yahoo
Sat, 02/18/17 - 02:22 pm
AbbVie
stock buyback
Pfizer says rheumatoid arthritis drug is comparable to Humira as combination treatment but not alone
Marketwatch
Thu, 02/16/17 - 03:13 pm
Pfizer
Xeljanz
AbbVie
Humira
rheumatoid arthritis
U.S. FDA Grants Priority Review to AbbVie for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)
Yahoo
Thu, 02/2/17 - 09:22 am
FDA
AbbVie
glecaprevir/pibrentasvir
G/P
hepatitis C
AbbVie Slides on Mixed Q4 Earnings
Yahoo/24-7 Wall St
Fri, 01/27/17 - 09:34 am
AbbVie
earnings
AbbVie’s Anti-Tau Antibody Enters Phase II Clinical Trials for Alzheimer’s Disease
Xtalks
Fri, 01/27/17 - 09:30 am
AbbVie
clinical trials
anti-tau antibodies
Alzheimer's disease
ABBV-8E12
AbbVie Gets FDA Approval for Lymphoma Drug
Yahoo/GuruFocus
Mon, 01/23/17 - 10:24 am
AbbVie
FDA
Imbruvica
marginal zone lymphoma
MZL
Earnings preview: 7 biopharmas to watch
BioPharma Dive
Sat, 01/21/17 - 11:49 am
earnings
JNJ
Novartis
Vertex Pharmaceuticals
Biogen
Celgene
Bristol-Myers Squibb
AbbVie
Boehringer Ingelheim's Humira Biosimilar Under Review by EMA, FDA
Yahoo/GuruFocus
Fri, 01/20/17 - 09:45 am
Boehringer Ingelheim
Humira
biosimilars
FDA
EMA
BI 695501
AbbVie
How Johnson & Johnson Beat Every Other Big Pharma Stock in 2016
Motley Fool
Thu, 01/19/17 - 11:26 am
JNJ
pharma stocks
AbbVie
Merck
This Army Vet Is Fighting Hep C With Big Pharma’s Help
Bloomberg
Thu, 12/29/16 - 10:18 am
hepatitis C
AbbVie
Merck
Gilead Sciences
3 Biggest Risks for AbbVie in 2017
Motley Fool
Wed, 12/28/16 - 11:03 am
AbbVie
Humira
biosimilars
Imbruvica
Viekira Pak
Elagolix
risankizumab
Galapagos, AbbVie glimpse early progress in search of a cystic fibrosis triple to rival Vertex
Endpoints
Wed, 12/21/16 - 11:10 am
Galapagos
AbbVie
Vertex Pharmaceuticals
cystic fibrosis
GLPG1837
AbbVie Files for Approval of Hepatitis C Treatment in the US
Yahoo/GuruFocus
Tue, 12/20/16 - 12:20 pm
AbbVie
hepatitis C
glecaprevir/pibrentasvir
Gilead's HCV NDA Means Nothing
Seeking Alpha
Sun, 12/11/16 - 11:55 am
Gilead Sciences
hepatitis C
SOF/VEL/VOX
Epclusa
AbbVie
Standing Up To The Test Of Time: Two Cancer Drugs That Could Survive A Hobbled FDA
Forbes
Thu, 12/8/16 - 09:59 am
FDA
Seattle Genetics
Takeda
Adcetris
Hodgkin's lymphoma
AbbVie
JNJ
Ibruvica
mantle cell lymphoma
AbbVie breast cancer drug falls short in Phase 2
BioPharma Dive
Wed, 12/7/16 - 07:45 pm
AbbVie
breast cancer
veliparib
PARP inhibitors
BRCA-mutant breast cancer
AbbVie and Johns Hopkins to Collaborate on Cancer Research
Yahoo
Mon, 12/5/16 - 09:55 am
AbbVie
Johns Hopkins
cancer
R&D
As Humira readies for biosimilar rivals, AbbVie looks to ASH to build oncology momentum
Fierce Pharma
Sat, 12/3/16 - 09:21 am
Humira
AbbVie
biosimilars
ASH
Pages
« first
‹ previous
…
42
43
44
45
46
47
48
49
50
…
next ›
last »